Biogen Idec Inc (BIIB) 276.99 $BIIB
Apple Upgraded To Buy; Amazon, McDonald's PTs Hiked
at Investor's Business Daily - 2 hrs 37 mins ago
Apple (AAPL) shares moved higher Friday after the iPhone maker was upgraded, while McDonald's (MCD) and Amazon (AMZN) got price-target hikes but Biogen's (BIIB) price target was cut. Maxim Group upgraded Apple to buy from hold and also raised its...
BIIB: 276.99 (+0.16), AMZN: 599.03 (+35.12), DNKN: 40.86 (+1.29), V: 77.07 (+0.65), MCD: 112.59 (+1.72), GOOGL: 719.33 (+38.19), MSFT: 52.87 (+4.84), AAPL: 119.08 (+3.58), CSCO: 29.35 (+0.34)
Acorda Up on Q3 Earnings & Revenue Beat, Ampyra in Focus
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 11:15AM CDT
Acorda Therapeutics' (ACOR) third-quarter 2015 earnings came in at 11 cents per share, while the Zacks Consensus Estimate was pegged at a loss of 12 cents.
AGN: 268.55 (+15.51), BIIB: 276.99 (+0.16), AMGN: 155.75 (+3.44), ACOR: 36.14 (+1.22)
Battle Royale: Amgen Inc. vs. Biogen Inc.
Keith Speights, The Motley Fool - Motley Fool - Fri Oct 23, 7:42AM CDT
Image source: Wikipedia.org . On the surface, Amgen and Biogen might not look like competitors. The two big biotechs don't go head-to-head with any of their major drugs. But there's one important way that Amgen and Biotech do battle against...
BIIB: 276.99 (+0.16), AMGN: 155.75 (+3.44)
3 Earnings Reports That Surprised Us
Matthew Frankel, Dan Caplinger, and Cheryl Swanson, The Motley Fool - Motley Fool - Fri Oct 23, 7:00AM CDT
Earnings season is well under way, and we've already had a few big surprises. Many companies surprised investors with unexpected changes, and many simply didn't come close to their expected performance. Here's why Alcoa , Biogen , and Morgan...
BIIB: 276.99 (+0.16), AA: 9.14 (+0.05), MS: 32.62 (+0.27)
Biogen's Beat, Raise, and Yawn
Brian Orelli, The Motley Fool - Motley Fool - Thu Oct 22, 8:45PM CDT
After a not-so-great second-quarter earnings release that sent its shares down 22%, it was refreshing to see Biogen beat earnings guidance and raise full-year guidance after its third-quarter earnings release. Shares were up 4% on Wednesday, and...
BIIB: 276.99 (+0.16), PFE: 34.05 (+0.72), TEVA: 59.55 (+3.59), NVS: 92.98 (+0.55)
Hurricane Hillary Shifts Left, Slamming More Stocks
at Investor's Business Daily - Thu Oct 22, 2:52PM CDT
Hillary Clinton has demonstrated a knack for striking fear in the hearts of investors -- first in pharmaceuticals, then in health insurance and now in cable TV. For example, the beginning of Valeant's (VRX) nearly 60% plunge in the last month can be...
BIIB: 276.99 (+0.16), VRX: 116.16 (+6.29), BMRN: 104.14 (+2.54), UNH: 115.92 (+2.11), CHTR: 183.00 (+4.62), AET: 105.89 (+2.53), HUM: 168.20 (+3.09), CI: 132.54 (+3.05), ANTM: 140.95 (+1.54), GILD: 107.99 (+0.39), TWC: 185.19 (+2.29), CMCSA: 61.98 (+0.28), REGN: 536.70 (+11.59)
Perrigo Beats on Q3 Earnings, Misses Revenues, Cuts Jobs
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 10:34AM CDT
Perrigo Company's (PRGO) third-quarter 2015 earnings of $1.76 per share beat the Zacks Consensus Estimate.
BIIB: 276.99 (+0.16), PRGO: 150.57 (+2.89), MYL: 40.96 (+1.80), TEVA: 59.55 (+3.59)
No Easy Cure for What Ails Biotech Stocks
at The Street - Thu Oct 22, 10:30AM CDT
Meanwhile, make incremental moves until the onslaught in the space is over.
BIIB: 276.99 (+0.16), VRX: 116.16 (+6.29), GILD: 107.99 (+0.39), MYL: 40.96 (+1.80), AMGN: 155.75 (+3.44)
Global Hemophilia A Market 2015-2019
M2 - Thu Oct 22, 9:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kmq3vn/global_hemophilia) has announced the addition of the "Global Hemophilia A Market 2015-2019" report to their offering. The global hemophilia A drugs market to grow at a CAGR of 6.25% over the period 2014-2019. The report, Global Hemophilia A Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC, Europe, and Americas; it also covers the landscape of the global hemophilia A drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. The report covers the current scenario and the growth prospects of the global hemophilia A drugs market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment and prevention of hemophilia A. In this report, the market is also segmented based on the type of therapy. There are new technological advancements in terms of drug manufacturing, development, and delivery. These advances has led to the development of recombinant products. For instance, animal or human plasma proteins are not used to manufacture NovoSeven, thereby decreasing the risk of infection. The use of Fc-fusion technology has increased the half-life of Eloctate in blood, thereby improving drug action. According to the report, the development of new hemophilia A therapeutics with prolonged action is prompting market growth. Vendors are developing a number of products, which are in the pipeline stage. The anticipated approval of these products will impact the growth of the market during the forecast period. Further, the report states that the high cost of treatment leads to the discontinuation of therapy, thereby hampering market growth. Key vendors - Baxter International - Bayer's - CSL Behring - Novo Nordisk - Pfizer Other prominent vendors - Alnylam Pharmaceuticals - Amarna Therapeutics - Asklepios - Biogen Idec - Catalyst Biosciences - Dimension Therapeutics - Dong-A Socio - Emergent BioSolutions - Grifols - Inspiration Biopharmaceuticals - Kedrion Biopharma - Octapharma - OPKO Health - rEVO Biologics - Sangamo BioSciences - Spark Therapeutics - UniQure For more information visit http://www.researchandmarkets.com/research/km...hemophilia
BIIB: 276.99 (+0.16), NVO: 55.72 (+2.07), EBS: 30.14 (+0.08), OPK: 9.45 (+0.42), ONCE: 61.81 (+2.85), BAX: 35.40 (+0.48), SGMO: 7.19 (+0.76), CBIO: 4.27 (-0.13), RBIO: (), DMTX: 12.25 (+1.45)
Biogen Idec (BIIB) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - Wed Oct 21, 8:41PM CDT
The following Biogen Idec (BIIB) conference call took place on October 21, 2015, 08:30 AM ET. This is a transcript of that earnings call:
BIIB: 276.99 (+0.16)
Biogen tops Q3, will cut jobs
at Investor's Business Daily - Wed Oct 21, 5:49PM CDT
The struggling biotech announced an 11% workforce reduction and the discontinuation of some clinical programs. Those savings, in part, prompted Biogen (BIIB) to raise full-year EPS guidance by more than 70 cents to $16.20-$16.50. It also lifted...
BIIB: 276.99 (+0.16)
Watch for Biogen Idec to Potentially Pullback After Gaining 3.96% Yesterday
Comtex SmarTrend(R) - Wed Oct 21, 3:42PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $262.45 to a high of $291.01. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $277.29 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 276.99 (+0.16)
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 3.96% Rise
Comtex SmarTrend(R) - Wed Oct 21, 3:42PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $262.45 to a high of $291.01. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $277.29 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 276.99 (+0.16)
Stocks Fall; Valeant Defends Accounting Practices
at The Street - Wed Oct 21, 2:02PM CDT
Stocks relinquish gains made earlier Wednesday as a selloff in Valeant Pharmaceuticals pressures the rest of the biotech sector.
TSLA: 209.09 (-2.63), BIIB: 276.99 (+0.16), F: 15.67 (+0.09), VRX: 116.16 (+6.29), KMB: 121.24 (+0.44), IBB: 316.28 (+10.17), TM: 125.74 (+0.51), SBUX: 62.61 (+1.12), YHOO: 33.17 (+1.50), CMG: 649.72 (-0.90), ABBV: 50.34 (+2.07), GOOGL: 719.33 (+38.19), HMC: 33.83 (+0.79), AAPL: 119.08 (+3.58), KO: 42.79 (-0.45), AMZN: 599.03 (+35.12), MU: 17.24 (+0.52), PFE: 34.05 (+0.72), LLY: 78.31 (+1.33), FCAU: 15.37 (+0.13), BMY: 65.16 (+1.98), BA: 146.70 (+0.39), WDC: 69.34 (-0.62), LRCX: 74.57 (+1.96), MCD: 112.59 (+1.72), GM: 35.95 (+0.53), KLAC: 65.35 (+0.45), RACE: 56.38 (-0.37), SNDK: 78.37 (+1.28)
Biogen Banks on High-Risk Drugs to Recapture Biotech Buzz
at The Street - Wed Oct 21, 12:46PM CDT
Biotech is a high-growth industry fueled by scientific innovation. The snapshot of Biogen Wednesday lacks the biotech buzz for which investors are willing to pay a premium.
BIIB: 276.99 (+0.16)
Biogen cutting 11 percent of its workforce
AP - Wed Oct 21, 12:39PM CDT
NEW YORK (AP) — Biogen plans to cut about 11 percent of its workforce as it refocuses its research on treatments for Alzheimer's disease and multiple sclerosis.
BIIB: 276.99 (+0.16)
Downtrend Call Working As Biogen Idec Stock Falls 8.2% (BIIB)
Comtex SmarTrend(R) - Wed Oct 21, 12:15PM CDT
SmarTrend identified a Downtrend for Biogen Idec (NASDAQ:BIIB) on September 25th, 2015 at $289.55. In approximately 4 weeks, Biogen Idec has returned 8.24% as of today's recent price of $265.68.
BIIB: 276.99 (+0.16)
Biogen To Cut 11% of Its Workforce As Part Of Restructuring Plan
Madeleine Johnson - Zacks Investment Research - Wed Oct 21, 11:31AM CDT
The biotech giant is also ending many of its drug development programs along with the workforce reduction.
WFM: 32.28 (-0.25), BIIB: 276.99 (+0.16), WMT: 58.30 (-0.60), TWTR: 30.28 (+1.13), HPQ: 29.03 (+0.26)
Here's Why Biogen (BIIB) Stock Is Climbing Today
at The Street - Wed Oct 21, 11:15AM CDT
Biogen (BIIB) stock is gaining in early afternoon trading on Wednesday, after reporting job cuts totaling 11% of its workforce and third quarter earnings results.
BIIB: 276.99 (+0.16)
Biogen Tops Q3 Earnings, Announces Job Cuts, Ups View
Arpita Dutt - Zacks Investment Research - Wed Oct 21, 10:40AM CDT
Biogen (BIIB) surpassed Q3 earnings expectations by a wide margin.
BIIB: 276.99 (+0.16), AMGN: 155.75 (+3.44), AEGR: 15.41 (-0.15)
Apple Upgraded To Buy; Amazon, McDonald's PTs Hiked
at Investor's Business Daily - 2 hrs 37 mins ago
Apple (AAPL) shares moved higher Friday after the iPhone maker was upgraded, while McDonald's (MCD) and Amazon (AMZN) got price-target hikes but Biogen's (BIIB) price target was cut. Maxim Group upgraded Apple to buy from hold and also raised its...
BIIB: 276.99 (+0.16), AMZN: 599.03 (+35.12), DNKN: 40.86 (+1.29), V: 77.07 (+0.65), MCD: 112.59 (+1.72), GOOGL: 719.33 (+38.19), MSFT: 52.87 (+4.84), AAPL: 119.08 (+3.58), CSCO: 29.35 (+0.34)
Acorda Up on Q3 Earnings & Revenue Beat, Ampyra in Focus
Zacks Equity Research - Zacks Investment Research - Fri Oct 23, 11:15AM CDT
Acorda Therapeutics' (ACOR) third-quarter 2015 earnings came in at 11 cents per share, while the Zacks Consensus Estimate was pegged at a loss of 12 cents.
AGN: 268.55 (+15.51), BIIB: 276.99 (+0.16), AMGN: 155.75 (+3.44), ACOR: 36.14 (+1.22)
Battle Royale: Amgen Inc. vs. Biogen Inc.
Keith Speights, The Motley Fool - Motley Fool - Fri Oct 23, 7:42AM CDT
Image source: Wikipedia.org . On the surface, Amgen and Biogen might not look like competitors. The two big biotechs don't go head-to-head with any of their major drugs. But there's one important way that Amgen and Biotech do battle against...
BIIB: 276.99 (+0.16), AMGN: 155.75 (+3.44)
3 Earnings Reports That Surprised Us
Matthew Frankel, Dan Caplinger, and Cheryl Swanson, The Motley Fool - Motley Fool - Fri Oct 23, 7:00AM CDT
Earnings season is well under way, and we've already had a few big surprises. Many companies surprised investors with unexpected changes, and many simply didn't come close to their expected performance. Here's why Alcoa , Biogen , and Morgan...
BIIB: 276.99 (+0.16), AA: 9.14 (+0.05), MS: 32.62 (+0.27)
Biogen's Beat, Raise, and Yawn
Brian Orelli, The Motley Fool - Motley Fool - Thu Oct 22, 8:45PM CDT
After a not-so-great second-quarter earnings release that sent its shares down 22%, it was refreshing to see Biogen beat earnings guidance and raise full-year guidance after its third-quarter earnings release. Shares were up 4% on Wednesday, and...
BIIB: 276.99 (+0.16), PFE: 34.05 (+0.72), TEVA: 59.55 (+3.59), NVS: 92.98 (+0.55)
Hurricane Hillary Shifts Left, Slamming More Stocks
at Investor's Business Daily - Thu Oct 22, 2:52PM CDT
Hillary Clinton has demonstrated a knack for striking fear in the hearts of investors -- first in pharmaceuticals, then in health insurance and now in cable TV. For example, the beginning of Valeant's (VRX) nearly 60% plunge in the last month can be...
BIIB: 276.99 (+0.16), VRX: 116.16 (+6.29), BMRN: 104.14 (+2.54), UNH: 115.92 (+2.11), CHTR: 183.00 (+4.62), AET: 105.89 (+2.53), HUM: 168.20 (+3.09), CI: 132.54 (+3.05), ANTM: 140.95 (+1.54), GILD: 107.99 (+0.39), TWC: 185.19 (+2.29), CMCSA: 61.98 (+0.28), REGN: 536.70 (+11.59)
Perrigo Beats on Q3 Earnings, Misses Revenues, Cuts Jobs
Zacks Equity Research - Zacks Investment Research - Thu Oct 22, 10:34AM CDT
Perrigo Company's (PRGO) third-quarter 2015 earnings of $1.76 per share beat the Zacks Consensus Estimate.
BIIB: 276.99 (+0.16), PRGO: 150.57 (+2.89), MYL: 40.96 (+1.80), TEVA: 59.55 (+3.59)
No Easy Cure for What Ails Biotech Stocks
at The Street - Thu Oct 22, 10:30AM CDT
Meanwhile, make incremental moves until the onslaught in the space is over.
BIIB: 276.99 (+0.16), VRX: 116.16 (+6.29), GILD: 107.99 (+0.39), MYL: 40.96 (+1.80), AMGN: 155.75 (+3.44)
Global Hemophilia A Market 2015-2019
M2 - Thu Oct 22, 9:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kmq3vn/global_hemophilia) has announced the addition of the "Global Hemophilia A Market 2015-2019" report to their offering. The global hemophilia A drugs market to grow at a CAGR of 6.25% over the period 2014-2019. The report, Global Hemophilia A Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC, Europe, and Americas; it also covers the landscape of the global hemophilia A drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. The report covers the current scenario and the growth prospects of the global hemophilia A drugs market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment and prevention of hemophilia A. In this report, the market is also segmented based on the type of therapy. There are new technological advancements in terms of drug manufacturing, development, and delivery. These advances has led to the development of recombinant products. For instance, animal or human plasma proteins are not used to manufacture NovoSeven, thereby decreasing the risk of infection. The use of Fc-fusion technology has increased the half-life of Eloctate in blood, thereby improving drug action. According to the report, the development of new hemophilia A therapeutics with prolonged action is prompting market growth. Vendors are developing a number of products, which are in the pipeline stage. The anticipated approval of these products will impact the growth of the market during the forecast period. Further, the report states that the high cost of treatment leads to the discontinuation of therapy, thereby hampering market growth. Key vendors - Baxter International - Bayer's - CSL Behring - Novo Nordisk - Pfizer Other prominent vendors - Alnylam Pharmaceuticals - Amarna Therapeutics - Asklepios - Biogen Idec - Catalyst Biosciences - Dimension Therapeutics - Dong-A Socio - Emergent BioSolutions - Grifols - Inspiration Biopharmaceuticals - Kedrion Biopharma - Octapharma - OPKO Health - rEVO Biologics - Sangamo BioSciences - Spark Therapeutics - UniQure For more information visit http://www.researchandmarkets.com/research/km...hemophilia
BIIB: 276.99 (+0.16), NVO: 55.72 (+2.07), EBS: 30.14 (+0.08), OPK: 9.45 (+0.42), ONCE: 61.81 (+2.85), BAX: 35.40 (+0.48), SGMO: 7.19 (+0.76), CBIO: 4.27 (-0.13), RBIO: (), DMTX: 12.25 (+1.45)
Biogen Idec (BIIB) Earnings Report: Q3 2015 Conference Call Transcript
at The Street - Wed Oct 21, 8:41PM CDT
The following Biogen Idec (BIIB) conference call took place on October 21, 2015, 08:30 AM ET. This is a transcript of that earnings call:
BIIB: 276.99 (+0.16)
Biogen tops Q3, will cut jobs
at Investor's Business Daily - Wed Oct 21, 5:49PM CDT
The struggling biotech announced an 11% workforce reduction and the discontinuation of some clinical programs. Those savings, in part, prompted Biogen (BIIB) to raise full-year EPS guidance by more than 70 cents to $16.20-$16.50. It also lifted...
BIIB: 276.99 (+0.16)
Watch for Biogen Idec to Potentially Pullback After Gaining 3.96% Yesterday
Comtex SmarTrend(R) - Wed Oct 21, 3:42PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $262.45 to a high of $291.01. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $277.29 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 276.99 (+0.16)
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 3.96% Rise
Comtex SmarTrend(R) - Wed Oct 21, 3:42PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $262.45 to a high of $291.01. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $277.29 on volume of 8.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 276.99 (+0.16)
Stocks Fall; Valeant Defends Accounting Practices
at The Street - Wed Oct 21, 2:02PM CDT
Stocks relinquish gains made earlier Wednesday as a selloff in Valeant Pharmaceuticals pressures the rest of the biotech sector.
TSLA: 209.09 (-2.63), BIIB: 276.99 (+0.16), F: 15.67 (+0.09), VRX: 116.16 (+6.29), KMB: 121.24 (+0.44), IBB: 316.28 (+10.17), TM: 125.74 (+0.51), SBUX: 62.61 (+1.12), YHOO: 33.17 (+1.50), CMG: 649.72 (-0.90), ABBV: 50.34 (+2.07), GOOGL: 719.33 (+38.19), HMC: 33.83 (+0.79), AAPL: 119.08 (+3.58), KO: 42.79 (-0.45), AMZN: 599.03 (+35.12), MU: 17.24 (+0.52), PFE: 34.05 (+0.72), LLY: 78.31 (+1.33), FCAU: 15.37 (+0.13), BMY: 65.16 (+1.98), BA: 146.70 (+0.39), WDC: 69.34 (-0.62), LRCX: 74.57 (+1.96), MCD: 112.59 (+1.72), GM: 35.95 (+0.53), KLAC: 65.35 (+0.45), RACE: 56.38 (-0.37), SNDK: 78.37 (+1.28)
Biogen Banks on High-Risk Drugs to Recapture Biotech Buzz
at The Street - Wed Oct 21, 12:46PM CDT
Biotech is a high-growth industry fueled by scientific innovation. The snapshot of Biogen Wednesday lacks the biotech buzz for which investors are willing to pay a premium.
BIIB: 276.99 (+0.16)
Biogen cutting 11 percent of its workforce
AP - Wed Oct 21, 12:39PM CDT
NEW YORK (AP) — Biogen plans to cut about 11 percent of its workforce as it refocuses its research on treatments for Alzheimer's disease and multiple sclerosis.
BIIB: 276.99 (+0.16)
Downtrend Call Working As Biogen Idec Stock Falls 8.2% (BIIB)
Comtex SmarTrend(R) - Wed Oct 21, 12:15PM CDT
SmarTrend identified a Downtrend for Biogen Idec (NASDAQ:BIIB) on September 25th, 2015 at $289.55. In approximately 4 weeks, Biogen Idec has returned 8.24% as of today's recent price of $265.68.
BIIB: 276.99 (+0.16)
Biogen To Cut 11% of Its Workforce As Part Of Restructuring Plan
Madeleine Johnson - Zacks Investment Research - Wed Oct 21, 11:31AM CDT
The biotech giant is also ending many of its drug development programs along with the workforce reduction.
WFM: 32.28 (-0.25), BIIB: 276.99 (+0.16), WMT: 58.30 (-0.60), TWTR: 30.28 (+1.13), HPQ: 29.03 (+0.26)
Here's Why Biogen (BIIB) Stock Is Climbing Today
at The Street - Wed Oct 21, 11:15AM CDT
Biogen (BIIB) stock is gaining in early afternoon trading on Wednesday, after reporting job cuts totaling 11% of its workforce and third quarter earnings results.
BIIB: 276.99 (+0.16)
Biogen Tops Q3 Earnings, Announces Job Cuts, Ups View
Arpita Dutt - Zacks Investment Research - Wed Oct 21, 10:40AM CDT
Biogen (BIIB) surpassed Q3 earnings expectations by a wide margin.
BIIB: 276.99 (+0.16), AMGN: 155.75 (+3.44), AEGR: 15.41 (-0.15)
